Biocept, a provider of molecular diagnostic assays, products and services announced a collaboration to provide laboratory testing services in lung cancer to patients of Quest Diagnostics.
The Biocept Target Selector NGS-based liquid biopsy assay is a lab developed test that can be used for genomic profiling in patients with advanced non-small cell lung cancer (NSCLC) to help qualify them for advanced targeted therapies and monitor the effectiveness of treatment.
With a physician’s order, patients will be able to provide a blood specimen for testing at one of Quest’s 2,200 patient service centers across the United States. The two parties expect the service to be available to Quest Diagnostics’ providers and patients in the fourth quarter of 2021.
